Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the earnings call transcript. The company maintains a strong liquidity position with cash and cash equivalents of INR1,682 crores. The focus is on utilizing existing cash and cash flows for organic expansion (e.g., oral solid facility ramp-up) and inorganic growth opportunities. Management emphasizes capital deployment in growth initiatives rather than external fundraising at this time. No comments were made on raising fresh capital through equity or debt during the call or in the discussed pages.

Any current/future capex/capital investment/strategic investment?

Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores. Ongoing expansion of the oral solid facility to support over 20% volume growth. Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway. No plans for new facilities or new dosage forms specifically for international CDMO; focus is on utilizing existing advanced injectable and hormone facilities. Evaluating inorganic opportunities in branded portfolios, though current market valuations are high. SAP S/4HANA digital transformation and Darwin

Future growth expectations in sales/revenue/volumes?

CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet. European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue. Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up. Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth. Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a

Future growth expectations in earnings/operating earnings/profits/EPS?

CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%). API business is expected to perform better than FY26 with reduced EBITDA losses; potential turnaround over next couple of quarters but full-year positivity uncertain. Trade generics business has turned EBITDA positive and is expected to maintain similar revenue and EBITDA levels without significant growth contribution. Domestic formulations aim for double-digit

Current/ Expected Orderbook/ Pending Orders?

The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years. For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores). The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28. The Zambia contract will contribute approximately $25 million annually in FY27 and FY28. These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals. The order book strength stems from established products and predictable volumes, with ongo

IN US

Sale is live|00:00:00left today

Akums Drugs & Pharmaceuticals LtdQ1 FY26Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹609P/E: 26.6Market Cap: ₹8.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet.
→European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue.
→Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up.
→Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth.
→Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a few quarters.
→Oral solid facility expansion underway to support volume growth.
→Broad-based gains from existing and new customers, including wallet share gains from competitors and in-house production.
→International CDMO customer base expected to expand to 8-10 global customers over 2-3 years.

Margin guidance

Category 3

→CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
→API business is expected to perform better than FY26 with reduced EBITDA losses; potential turnaround over next couple of quarters but full-year positivity uncertain.
→Trade generics business has turned EBITDA positive and is expected to maintain similar revenue and EBITDA levels without significant growth contribution.
→Domestic formulations aim for double-digit top-line growth in FY27, driven by price, volume, and NII growth, recovering in line with overall Indian Pharmaceutical Market (IPM).
→Overall margin improvements and profitability to come from ramping up new facilities, operational leverage, and inorganic opportunities.
→Tax rate expected around 29% going forward as API and trade generics businesses improve.
→No explicit guidance on EPS but improving profitability and operating leverage indicate positive earnings momentum.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no explicit mention of any current or planned fundraising through debt or equity in the earnings call transcript.
→The company maintains a strong liquidity position with cash and cash equivalents of INR1,682 crores.
→The focus is on utilizing existing cash and cash flows for organic expansion (e.g., oral solid facility ramp-up) and inorganic growth opportunities.
→Management emphasizes capital deployment in growth initiatives rather than external fundraising at this time.
→No comments were made on raising fresh capital through equity or debt during the call or in the discussed pages.

Order book

Yes

→The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years.
→For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores).
→The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28.
→The Zambia contract will contribute approximately $25 million annually in FY27 and FY28.
→These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals.
→The order book strength stems from established products and predictable volumes, with ongoing efforts in tech transfer and new product development.
→The company is consciously evaluating multiple growth opportunities but awaiting alignment on valuation and standards before capital deployment.

Capex plans

Yes

→Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
→Ongoing expansion of the oral solid facility to support over 20% volume growth.
→Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway.
→No plans for new facilities or new dosage forms specifically for international CDMO; focus is on utilizing existing advanced injectable and hormone facilities.
→Evaluating inorganic opportunities in branded portfolios, though current market valuations are high.
→SAP S/4HANA digital transformation and Darwinbox HR implementation underway for operational efficiency.
→Acquisition and expansion of land in Haridwar for capacity expansion and utility support.
→Capital deployment focus on organic expansions and strategic inorganic acquisitions aligned with growth and returns.

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Akums Drugs & Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio